A MULTICENTER OPEN-LABEL CONTINUATION STUDY IN MODERATE TO SEVERE CHRONIC PLA

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Psoriasis is a chronic immunologic disease characterized by marked inflammation and thickening of the epidermis that results in thick, scaly plaques involving the skin. It affects 1-3% of the general population, with the highest disease prevalence in North America and Europe. Psoriasis equally affects men and women, with peak onset of symptoms in young adults and again in the mid 50's. Genetic factors may predispose a person to psoriasis and psoriasis may be induced or exacerbated by exogenous triggers such as physical trauma, medications, infections, and emotional stress. Plaque psoriasis is the most common form seen in 75-80% of psoriasis patients. Treatment depends on the extent and severity of disease. Topical corticosteroids are commonly used for mild to moderate cases. Other topicalmedications include keratolytic agents, anthralin, coal tar, vitamin D analogs, and retinoids. For more widespread disease, phototherapy is commonly used.Systemic therapy, including methotrexate, cyclosporine and systemic retinoids are often effective in patients with moderate or severe disease. Due to the potential adverse side effects of systemic agents, these medications are generally administered in rotation to avoid long-term or cumulative toxicities.